• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Scientists invited to access UCB’s technology platform

Scientists invited to access UCB’s technology platform

May 1, 2014
CenterWatch Staff

UCB has launched its Technology Platform Access, a collaboration program for the discovery and development of novel antibodies against potential therapeutic targets.

Medicine discovery integrates scientific innovation with cutting-edge technology, and through the program academic and research groups can apply to gain access to UCB’s new, automated antibody discovery platform, which can generate, select, produce and evaluate new human antibody-based medicines for patients.

Ismail Kola, executive vice president, UCB NewMedicines, said, “Partnerships between academic groups and industry are vital to the future of scientific discovery. We are hugely committed to seeking new ways of working and creating super-networks to advance medical research and improve health. This program offers the chance for groups to access our state-of-the-art technology as well as collaborate with our premier discovery team.”

In December 2013, UCB announced the successful completion of a $5.5 million investment in a new laboratory with cutting-edge robotic equipment for the fully automated discovery of antibodies. This has permitted the company to greatly increase its antibody discovery capacity and coincides with the successful conclusion of a project to develop new technology to mine the natural repertoire of antibody sequence.

In conjunction with strong antibody engineering and expression capabilities, plus structural biology expertise, this represents a novel and efficient route to the generation of high-quality antibodies, not only against human targets, but also for the generation of research tools for proof-of-concept models.

UCB is accepting proposals from academic and research groups for collaborative projects on antibody targets, using this antibody discovery platform at its immunology research center of excellence facility in the U.K.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing